These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 18458118)

  • 1. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
    Dicato M
    Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
    Spano JP; Khayat D
    Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
    Spaëth D
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update.
    Aapro MS
    Oncologist; 2008; 13 Suppl 3():1-3. PubMed ID: 18458117
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J; Tonia T; Schwarzer G
    Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia management in oncology and hematology.
    Spivak JL; Gascón P; Ludwig H
    Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.